Retrospective review of D-dimer testing for venous thrombosis recurrence risk stratification: is this a useful test in the real world?
- PMID: 32253709
- DOI: 10.1007/s11239-020-02101-y
Retrospective review of D-dimer testing for venous thrombosis recurrence risk stratification: is this a useful test in the real world?
Abstract
Predicting the risk of recurrence after venous thromboembolism (VTE) remains an important clinical challenge. Post-anticoagulation cessation D-dimer has previously been shown to be associated with increased VTE recurrence in unprovoked major VTE, however this is not routinely used clinically and has not been validated in provoked VTE and isolated distal DVT (IDDVT). We aimed to retrospectively evaluate this practice in the real-world setting including examining its use in provoked VTE and IDDVT. Consecutive patients diagnosed with DVT or PE between January 2013 and December 2016 were retrospectively evaluated. Clinical features, VTE risk factors, recurrence and bleeding rates were evaluated for patients with normal and abnormal post-anticoagulation D-dimer, as well as those patients who did not undergo D-dimer testing. Patients with active malignancy, superficial vein thrombosis and inadequate follow-up were excluded. Of the 1033 patients with a diagnosis of VTE in the study period, 173 were included in the "D-dimer tested" group, and 254 in the "D-dimer un-tested" comparison group. Abnormal post-anticoagulation D-dimer was significantly associated with VTE recurrence (HR 5.96, 95% CI 2.15-14.57, p < 0.001). Abnormal D-dimer was also associated with high risk of VTE recurrence in travel-provoked VTE (67.61 events per 100 patient-years), and unprovoked IDDVT (HR 14.37, 95% CI 1.75-117.83, p = 0.013). Males with abnormal post-anticoagulation D-dimer were associated with the highest risk of VTE recurrence (HR 12.95, 95% CI 2.78-60.20, p = 0.001). Patients with unprovoked proximal DVT and/or PE who underwent D-dimer testing had a lower VTE recurrence rate compared to those who did not have D-dimer testing (HR 0.28, 95% CI 0.10-0.80, p = 0.017). We confirm the utility of post-anticoagulation cessation D-dimer testing to stratify VTE recurrence risk in the real-world setting, including potentially a role of this assay for predicting subsequent VTE in travel-provoked VTE and unprovoked IDDVT.
Keywords: D-dimer; Post-anticoagulation risk stratification; Recurrence; Venous thromboembolism.
Similar articles
-
D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis.Thromb Haemost. 2011 May;105(5):837-45. doi: 10.1160/TH10-08-0559. Epub 2011 Feb 28. Thromb Haemost. 2011. PMID: 21359409
-
D-dimer at venous thrombosis diagnosis is associated with risk of recurrence.J Thromb Haemost. 2017 May;15(5):917-924. doi: 10.1111/jth.13648. Epub 2017 Feb 24. J Thromb Haemost. 2017. PMID: 28166605
-
Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis.Thromb Res. 2017 Jun;154:35-41. doi: 10.1016/j.thromres.2017.04.002. Epub 2017 Apr 4. Thromb Res. 2017. PMID: 28407492 Clinical Trial.
-
Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.Ann Intern Med. 2010 Oct 19;153(8):523-31. doi: 10.7326/0003-4819-153-8-201010190-00009. Ann Intern Med. 2010. PMID: 20956709 Review.
-
D-dimer testing in the diagnosis of acute venous thromboembolism.Thromb Haemost. 1999 Aug;82(2):688-94. Thromb Haemost. 1999. PMID: 10605769 Review.
Cited by
-
D-dimer after 3 months of anticoagulation therapy and outcomes in cancer-associated isolated distal deep vein thrombosis.Blood Vessel Thromb Hemost. 2025 Feb 24;2(2):100063. doi: 10.1016/j.bvth.2025.100063. eCollection 2025 May. Blood Vessel Thromb Hemost. 2025. PMID: 40766276 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical